ArkadiuszZbigniewDudekMDPhD, FACP

PubMed

• Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
  Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane
  Melanoma Research. 2024-12-01
• Improving Patient Understanding and Outcomes in Lung Cancer Using an Animated Patient's Guide with Visual Formats of Learning.
  Manish R Patel, Abbie Begnaud, Shanda H Blackmon, Arkadiusz Z Dudek, Naomi Fujioka
  Journal of Cancer Education. 2024-10-22
• Convolutional Neural Networks for Segmentation of Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance).
  Mena Shenouda, Eyjólfur Gudmundsson, Feng Li, Christopher M Straus, Hedy L Kindler
  Journal of Imaging Informatics in Medicine. 2024-09-12

Journal Articles

• Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era  
  Abern MR1, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ, Anticancer Res, 5/1/2014
• Radiation recall reaction causing cardiotoxicity  
  Masri SC, Misselt AJ, Dudek A, Konety SH, J Cardiovasc Magn Reson, 4/22/2014
• Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors  
  Ganesan C1, Obulareddy SJ, Fischer JH, Antonysamy MA, Jha G, Bliss RL, Dudek AZ, Am J Clin Oncol, 2/26/2014
• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial  
  Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Joh..., Lancet Oncol, 1/1/2014
• SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours  
  Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN, Br J Cancer, 12/3/2013
• Antineoplastic activity of zoledronic acid and denosumab  
  Zwolak P, Dudek AZ, Anticancer Res, 8/1/2013
• Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy  
  Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, Dudek AZ, Salazar AM, Ohlfest JR, J Immunol, 5/17/2013
• "Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients"  
  Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P, Dermatol Surg, 4/1/2013
• Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer  
  Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, Dudek AZ, Muller-Mattheis V, Grimm MO, Gschwend JE, Wulfing C, Albers P, Li J, Osmukhina A, Skol..., Invest New Drugs, 1/18/2013
• Mechanisms Limiting Distribution of the BRAFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases  
  Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF, J Pharmacol Exp Ther, 12/17/2012
• Inhibition of mesothelin as a novel strategy for targeting cancer cells  
  Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olyaee MS, Esfandyari T, Farassati F, PLoS One, 4/2/2012
• Cancer and Leukemia Group B Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report  
  Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL, J Thorac Oncol, 4/1/2012
• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial  
  Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA, Lancet Oncol, 3/23/2012
• Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors  
  Chi M, Dudek AZ, Wind KP, Onkologie, 3/15/2012
• Phase II Study of Panobinostat and Bortezomib in Patients with Pancreatic Cancer Progressing on Gemcitabine-based Therapy  
  Wang H, Cao Q, Dudek AZ, Anticancer Res, 3/1/2012
• Large-cell neuroendocrine carcinoma of the cervix  
  Yoseph B, Chi M, Truskinovsky AM, Dudek AZ, Rare Tumors, 1/2/2012
• A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer  
  Clement-Duchene C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA, Lung Cancer, 1/1/2012
• Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)  
  Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL, Lung Cancer, 12/22/2011
• A phase 2 trial of dasatinib in advanced melanoma  
  Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M, Cancer, 5/15/2011
• Exploring Complex Networks with Graph Investigator Research Application  
  W. Czech, W. Dzwinel, S. Goryczka, T. Arodz, A.Z. Dudek, Computing and Informatics, 1/1/2011
• Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors  
  V Bodempudi, J R Ohlfest, K Terai, E A Zamora, R I Vogel, K Gupta, R P Hebbel, and A Z Dudek, Cancer Gene Therapy, 12/1/2010
• Tumor Angiogenesis (Editorial)  
  Dudek AZ, Gupta K, Ramakrishnan S,and Mukhopadhyay D, Journal of Oncology, 1/1/2010
• Treatment of Melanoma-Associated Retinopathy  
  Powell SF, Dudek AZ, Current Treatment Options in Neurology, 1/1/2010
• Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer  
  Leone JP, Dudek AZ, Anticancer Res, 11/1/2008
• Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial  
  Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group (Dudek AZ), J Natl Cancer Inst, 10/1/2008
• Join now to see all

Books/Book Chapters

• Devita, Hellman and Rosenberg's Cancer Review 
  Chapter: Treatment of Metastatic Cancer. 
  Dudek AZ, Govindan, RLippincott Williams & Wilkins, Hagerstwon2009
• Tumor Angiogenesis Frontiers in Anti-Cancer Drug Discovery 
  Chapter: Review of Selected Patents for Cancer Therapy Targeting. 
  Page 741 - 757M.N. Kirstein, A.Z. Dudek

Abstracts/Posters

• "Melanoma and Glioblastoma Multiforme 2011 ASCO Abstracts"
  Arkadiusz Dudek, MD, PhD, Best of ASCO Ecuador-2011, Salinas, Ecuador, 7/29/2011
• Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carci...
  Figlin R. A., Nicolette C. A., Amin A., Dudek A., Logan T., Lance R. S., Holzbeierlein J. M., Pal S. K., Master V. A., DeBenedette M., Tcherepanova I.Y., Jain R., Wil..., J Clin Oncol, 1/1/2011
• Clinical evaluation of food effects on pharmacokinetics of the novel oral taxane, tesetaxel.
  Danesi H., Dudek A., Spindler E., Alcorn Jr H, J Clin Oncol, 1/1/2011
• Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria.
  Ding L., Bliss R. L., Ingebrand M., Allen T., Ives P., Dudek A., Kratzke R. A, J Clin Oncol, 1/1/2011
• Phase II study of topotecan and bevacizumab in advanced refractory non-small cell lung cancer (NSCLC).
  Powell S. F., Beitinjaneh A., Bliss R. L., Kratzke R. A., Leach J. W., Dudek A, J Clin Oncol, 1/1/2011
• Myricetin a novel natural antineoplastic agent decreases progression of human pancreatic cancer via inhibition of akt kinase and erk pathways.
  Zwolak P., Borja-Cacho D., Phillips P., Dudeja V., Dawra R. K., Talukdar R., Chugh R. K., Dudek A. Z., Vickers S. M., Saluja A. K., 3rd Annual Academic Surgical Congress, Huntington Beach, CA, 2/13/2008
• Phase II Trial of Neoadjuvant Therapy with Carboplatin and Gemcitabine with Thalidomide in Patients with Stage IIB and IIIA Non-Small Cell Lung Cancer.
  Dudek AZ, Lesniewski-Kmak K, Koca N., Chereddy S., Maddaus, M, Dhlber P. Kratzke, R, ESMO Conference, Lugano, Switzerland, 1/1/2007
• CALGB 30306: A phase II study of cisplatin, irinotecan and bevacizumab for untreated extensive stage small cell lung cancer.
  Ready N, Dudek AZ, Wang XF, Graziano S, Green MR, Vokes EE, ASCO Annual Meeting Proceedings, 1/1/2007
• Phase I study of bortezomib plus cetuximab in patients with tumors expressing epidermal growth factor receptor.
  Dudek AZ, Gada P, Mullamala K, Shehadeh N, ASCO Annual Meeting Proceedings, 1/1/2007
• Sequential Therapy with Sorafenib and Sunitinib in Renal Cell Carcinoma.
  Dham A, Dudek AZ, ASCO Annual Meeting Proceedings, 1/1/2007
• Zoledronic acid release from polymethylmethacrylate carrier and in vitro activity against giant cell tumor of bone.
  Zwolak P, Manivel C, Jasinski P, Fisher J, Kirstein MN, Dudek AZ, Cheng EY, MSTS Meeting, Italy, 11/10/2006
• Selective protein kinase C-beta inhibitor (Enzastaurin) suppresses tumor growth, bone osteolysis, cancer -induced bone pain, and enhance radiosensitivity of the bone t...
  AACR Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment, Chicago, IL, 9/12/2006
• Initial results of a phase II study of biweekly pemetrexed and gemcitabine in patients with advanced NSCLC.
  Dudek AZ, Larson T, McCleod M, Schneider DJ, Dowell JE, Ye Z, Cunneen J, Monberg M, Tai F, Obasaju CK, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 6/20/2006
• A phase I clinical study of biweekly carboplatin and gemcitabine in patients with advanced solid tumors.
  Kumar P, Keshtgarpour M, Kumar H, Dudek AZ, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 6/20/2006
• A phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy.
  Mekhail T, Serwatowski P, Dudek AZ, Belani C, Jankowska R, Pandya KJ, Arnold S, Brahmer J, Gitlitz B, Govindan R, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 6/20/2006
• Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).
  Jahan TM, Gu L, Wang X, Kratzke RA, Dudek AZ, Green MR, Vokes EE, Kindler HL, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 6/20/2006
• Anti-angiogenic therapy and local irradiation exhibit additive effects in decreasing tumor burden and reducing bone cancer pain.
  Zwolak P, Goblirsch P, Nelson N, Clohisy DR, Dudek AZ, "Skeletal Complications of Malignancy" Meeting in Bethesda, 4/28/2005
• Therapy with antibody to VEGF in combination with megavoltage irradiation improves control of metastatic renal cell carcinoma of bone.
  Zwolak P, Nelson C, Goblirsch M, Clohisy DR. Dudek AZ, Immune, vascular and gene targeting for cancer imaging and therapy-Meeting, San Diego, 2/28/2005
• Autologous large multivalent immunogen vaccine for the treatment of stage IV malignant melanoma and stage IV renal cell carcinoma.
  Dudek AZ, Math V, Mescher M, Miller, J, Proceedings of the ECCO, 1/1/2005
• Immune Response Activation With a Toll-like Receptor 7Agonist: Results of a Phase 1 Study.
  Dudek AZ, Yunis C, Kumar S, Harrison, L, Hawkinson R, Miller J, Meeting Proceedings of the ASCO, 1/1/2005
• "Anti-angiogenic therapy and local irradiation exhibit additive effects in decreasing tumor burden and reducing bone cancer pain."
  Zwolak P. Goblirsch M, Nelson C, Clohisy DR, Dudek AZ, Journal of Bone and Mineral Research, 1/1/2005
• Preclinical Evaluation of MT103, a postulated novel protein kinase C modulator: Validation of drug discovery methods based on molecular topology.
  Dudek AZ, Griffin R, Nelson CM, Ghandi L, Terai K, Ugaz E, Galvez J, Proceedings of the AACR, 1/1/2005
• Blood Outgrowth Endothelial Cells (BOEC) Contribute to Tumor Vascularization and Can Be Used for Delivery of Cancer Gene Therapy.
  Dudek AZ, Bodempudi V, Nelson C, Chang L, Hebbel RP, Blood, 1/1/2004
• Anti-Angiogenic Therapy Delivered By Blood Outgrowth Endothelial Cells Reduces Tumor Vessel Number In Mice With Lewis Lung Carcinoma.
  Dudek A, Marker P, Botner D, Hagen D, Chang L, Hebbel R, Proceedings of the AACR, 1/1/2002
• Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Levels Change After Chemotherapy In Non-Small Cell Lung Cancer Patients-Correlation with Tumor Re...
  Dudek A, Mahaseth H, Proceedings of the AACR, 1/1/2002
• Join now to see all

Lectures

• Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression afte... 
  2019 ASCO Annual Meeting - 6/1/2019
• Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Grand Rounds: "Tailoring Oncology Care with Genomics" 
  Department of Medicine, University of Illinois - 5/28/2013
• "Individualized Medicine-Tailoring Patient Care with Genomic Profiling of Melanoma" 
  Mayo Clinic, Rochester, MN - 5/18/2013
• "Translational Research Approaches to Reduce Health Disparities in Lung Disease" 
  University of Illinois - 9/10/2012
• "A phase II study of dasatinib in patients with previously treated malignant mesothelioma: CALGB 30601" 
  Kyoto, Japan - 8/31/2010
• "Management of Early Stage Non-Small Cell Lung Cancer" 
  University of Minnesota - 11/12/2009
• "Large Multivalent Immunogen Vaccine in Patients with Metastatic Melanoma" 
  Kos, Greece - 10/17/2008
• "Blood Outgrowth Endothelial Cell-based Delivery of Cancer Gene Therapy" 
  Kos, Greece - 10/17/2008
• "Outcome of High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: Single Institution Experience" 
  Stockholm, Sweden - 9/12/2008
• "Management of Advanced Lung Cancer" 
  Hennepin Medical Center, Minneapolis, MN - 3/13/2008
• Grand Rounds: "Management of Advanced Malignant Melanoma" 
  Department of Dermatology, University of Minnesota - 1/9/2008
• "Prognostic Significance of Molecular and Clinical Factors in Stage IB NSCLC: A Laboratory Companion Study to CALGB 9633" 
  Seoul, South Korea - 9/2/2007
• "Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stage II and IIIA Non-Small Cell Lung Cancer (NSCLC)" 
  Lugano, Switzerland - 7/5/2007
• "Targeted therapy in Ovarian Carcinoma" 
  University of Minnesota - 5/1/2007
• "Management of Invasive and Metastatic Bladder Cancer" 
  University of Minnesota - 12/1/2006
• "Diagnosis Imaging and Treatment of C.N.S. Tumors" 
  University of Minnesota - 12/1/2006
• "Novel Gemcitabine Doublets in NSCLC Treatment" 
  University of Minnesota - 11/1/2006
• "Malignant Pleural Mesothelioma" 
  University of Minnesota - 10/1/2006
• "New Approaches to Lung Cancer: Translating Clinical Research into Clinical Practice" 
  Iowa City, IA - 9/1/2006
• "Second Line Chemotherapy for Advanced Non-Small Cell Lung Cancer" 
  Detroit, MI - 4/1/2006
• "Reducing Toxicities Associated with Treatment of Gastrointestinal Malignancies" 
  Chicago, IL - 4/1/2006
• "Modern Management of Kidney Cancer" 
  University of Minnesota - 3/1/2006
• "Modern Management of Non-Small Cell Lung Cancer" 
  University of South Dakota - 11/1/2005
• "Thoracic Oncology and Primary Care" 
  University of Minnesota - 11/1/2005
• Join now to see all